← Eichor
Study identifier: NCT05911230 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases

Condition: Glioblastoma (GBM)  ·  Sponsor: University Hospital, Basel, Switzerland

PhaseNA
Planned participants10
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.

This description comes directly from the study's public registry record.

Talk to the study team

Dominik Cordier, PD Dr. med.  ·  +41 61 26 56 42  ·  dominik.cordier@usb.ch

Always discuss trial participation with your own doctor first.

Locations (1)

University Hospital BaselBasel, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05911230